Sotatercept-csrk - Biologic Drug Details

Summary for sotatercept-csrk

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for sotatercept-csrk Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for sotatercept-csrk Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	WINREVAIR	sotatercept-csrk	For Injection	761363	7,612,041	2026-11-22	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	WINREVAIR	sotatercept-csrk	For Injection	761363	7,951,771	2028-09-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for sotatercept-csrk Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for sotatercept-csrk

Country	Patent Number	Estimated Expiration
Japan	2013153765
Israel	259893
Taiwan	I606062
Ukraine	98447
Japan	2013224317
Hong Kong	1137366

Market Dynamics and Financial Trajectory for Sotatercept-csRK

Last updated: February 16, 2026

Overview of Sotatercept-csRK

Sotatercept-csRK (trade name pending approval) is a biologic agent developed by Acceleron Pharma, targeting conditions related to pulmonary arterial hypertension (PAH) and bone marrow disorders. It functions as a ligand trap that modulates the TGF-beta superfamily signaling, primarily impacting erythropoiesis and vascular remodeling processes.

Market Landscape and Competitive Position

The biologic market for PAH therapies is highly concentrated. The global PAH drug market was valued at approximately $4.8 billion in 2022 and is projected to reach $6.4 billion by 2030, with a CAGR of around 4.1% between 2023 and 2030 [1]. Existing therapies include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclins. Limitations of current options—such as limited efficacy in advanced cases and side effect profiles—create significant unmet needs.

Sotatercept's development aims to provide a new mechanism of action, differentiating from existing treatments. Its potential indications extend into anemia associated with chronic diseases and bone marrow failure syndromes, opening additional markets.

Regulatory Status and Data Milestones

• Phase 3 trials (ATAINS and PULSAR) in PAH demonstrated improvements in exercise capacity and hemodynamics.
• The FDA granted fast track designation for PAH in 2021.
• NDA submission expected in late 2023, with potential FDA approval in early 2024.

The approval timeline influences market entry timing and valuation.

Market Penetration Potential and Adoption Dynamics

Market access depends on:

• Demonstrated superior efficacy over existing therapies.
• Safety profile, especially concerning adverse events observed in trials.
• Pathways for reimbursement, considering pricing strategies and health insurance coverage.

Early Companion diagnostics to identify suitable patient populations can accelerate adoption.

Financial Trajectory and Revenue Projections

• Revenue potential hinges on market penetration rate, pricing, and patient pool size.
• Estimated target population in PAH: approximately 75,000 diagnosed globally, with 30% receiving treatment.
• Pricing assumptions: $150,000 annually per patient, aligning with current biologic therapies in PAH.

Initial annual revenue estimates:

Year	Market Penetration	Estimated Patients	Revenue (USD millions)
2024	5%	1,125	169
2025	10%	2,250	338
2026	20%	4,500	675

In alternative indications, revenue could ingress as clinical validation emerges.

Cost Structure and Profitability Outlook

Research and development expenditures for Sotatercept are substantial, with annual R&D costs around $250 million pre-commercialization. Manufacturing costs for biologics typically represent 20-30% of product price. Marketing and sales expenses for biologic drugs in specialty markets can reach $100-150 million annually post-approval.

Profitability timelines depend on approval, patent life, and reimbursement pace.

Risk Factors Impacting Financial Trajectory

• Clinical trial results do not meet primary endpoints.
• Regulatory delays or denials.
• Competitive launch by existing or emerging therapies.
• Payer resistance to high-cost biologics.

---

Key Takeaways

• Sotatercept-csRK is positioned as a potential novel treatment for PAH and related conditions.
• Market entry hinges on successful Phase 3 results, regulatory approval, and payer acceptance.
• Revenue projections suggest modest initial growth, expanding with adoption and potential expansion into additional indications.
• Cost management and strategic market access are crucial for profitability.

FAQs

1. What distinguishes sotatercept from other PAH treatments?
It operates via TGF-beta pathway modulation, offering a different mechanism of action from current vasodilators, potentially benefiting patients unresponsive to existing therapies.

2. When is sotatercept expected to launch commercially?
FDA submission is anticipated in late 2023, with approval possibly in early 2024, pending review outcomes.

3. What are the main financial risks associated with sotatercept?
Clinical trial failures and inability to achieve targeted market share could significantly affect revenue projections.

4. How competitive is the PAH drug market for sotatercept?
It is highly competitive, dominated by established therapies, but sotatercept's novel mechanism may allow differentiation.

5. Are there additional markets for sotatercept beyond PAH?
Yes. Its mechanism suggests potential in anemia management and bone marrow disorders, expanding its commercial footprint if approved for those indications.

---

Citations

[1] GlobalData, "Pulmonary Hypertension Market," 2022.